| Literature DB >> 36096936 |
Yoshihisa Ohashi1, Kensuke Fukushima2, Kentaro Uchida1, Tomohisa Koyama1, Maho Tsuchiya1, Hiroki Saito1, Katsufumi Uchiyama3, Naonobu Takahira4, Gen Inoue1, Masashi Takaso1.
Abstract
We investigated the differences in outcomes after total hip arthroplasty (THA) for hip osteoarthritis (HOA) between patients with and without central sensitivity syndromes (CSSs) other than fibromyalgia (FM). After excluding two patients with FM, we compared the clinical data of 41 patients with CSSs and 132 patients without CSSs. Clinical data included scores on the central sensitization inventory, visual analog scale for pain (VAS pain), and Japanese Orthopedic Association Hip Disease Evaluation Questionnaire (JHEQ). VAS pain was significantly higher at 3 and 6 months after THA in patients with CSSs than in those without CSSs (3 and 6 months, P < 0.001). Satisfaction, pain, and mental JHEQ scores were lower in patients with CSSs than in those without CSSs (satisfaction, P < 0.001; pain, P = 0.011; mental, P = 0.032). Multiple regression analyses indicated that one and ≥ 2 CSS diagnoses significantly impacted the satisfaction score (one CSS, β = - 0.181, P = 0.019; ≥ 2 CSSs, β = - 0.175, P = 0.023). Two or more CSSs were the only factor influencing the pain score (β = - 0.175, P = 0.027). Pain in patients with CSSs reflects central sensitization, which may adversely affect post-operative outcomes. Surgeons should pay attention to patients with a history of CSSs diagnoses who undergo THA for HOA.Entities:
Mesh:
Year: 2022 PMID: 36096936 PMCID: PMC9468138 DOI: 10.1038/s41598-022-19369-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Flowchart of the study. HOA hip osteoarthritis, THA total hip arthroplasty, CSS central sensitivity syndrome.
Central sensitivity syndrome prevalence in patients with hip osteoarthritis (N = 175).
| N (%) | |
|---|---|
| Migraine or tension headaches | 14 (8.0) |
| Neck injury, including whiplash | 13 (7.4) |
| Depression | 10 (5.7) |
| Temporomandibular joint disorder | 9 (5.1) |
| Irritable bowel syndrome | 3 (1.7) |
| Anxiety or panic attacks | 2 (1.1) |
| Fibromyalgia | 2 (1.1) |
| Restless leg syndrome | 1 (0.6) |
| Multiple chemical sensitivities | 1 (0.6) |
| Chronic fatigue syndrome | 1 (0.6) |
| 32 (18.3) | |
| 8 (4.6) | |
| 2 (1.1) | |
| 1 (0.6) | |
CSS central sensitivity syndrome.
Demographic and clinical factors.
| Patients without CSSs | Patients with CSSs | P-values | |
|---|---|---|---|
| Sex, male/female, N | 25/107 | 1/40 | |
| Age (years) | 64.9 ± 1.0 | 63.8 ± 1.9 | 0.819 |
| Height (cm) | 156.1 ± 0.7 | 155.2 ± 0.9 | 0.959 |
| Weight (kg) | 60.3 ± 1.3 | 59.0 ± 2.0 | 0.996 |
| Body mass index (kg/m2) | 24.6 ± 0.4 | 24.4 ± 0.7 | 0.828 |
| Hip osteoarthritis grade (KL 3/4), N | 48/84 | 15/26 | 0.875 |
| Duration of hip pain (months) | 51.7 ± 4.3 | 44.4 ± 6.6 | 0.408 |
| CSI score | 18.5 ± 0.9 | 28.0 ± 1.8 |
The results are expressed as the mean ± standard error of the mean, unless otherwise indicated.
Statistically significant P-values (< 0.05) are indicated in bold.
CSS central sensitivity syndrome, KL Kellgren–Lawrence, CSI central sensitization inventory.
Correlations between the pre-operative central sensitization inventory score and post-operative clinical outcomes in patients with and without central sensitivity syndromes.
| VAS pain | VAS satisfaction | Pain score | Function score | Mental score | Total score | |
|---|---|---|---|---|---|---|
| Patients with CSSs (N = 41) | ρ = 0.201 | ρ = − 0.204 | ρ = − 0.097 | ρ = − 0.116 | ρ = − 0.301 | ρ = − 0.224 |
| P = 0.213 | P = 0.206 | P = 0.550 | P = 0.450 | P = 0.059 | P = 0.164 | |
| Patients without CSSs (N = 132) | ρ = 0.081 | ρ = 0.039 | ρ = − 0.291 | ρ = − 0.209 | ρ = − 0.334 | ρ = − 0.305 |
| P = 0.353 | P = 0.654 | P < 0.001‡ | P = 0.016* | P < 0.001‡ | P < 0.001‡ |
VAS satisfaction, pain, function, mental, and total scores were examined using the Japanese Orthopaedic Association Hip-Disease Evaluation Questionnaire. Correlation coefficient is represented by ρ. P < 0.05 indicates statistical significance. *P < 0.05 and ‡P < 0.001.
CSI central sensitization inventory, VAS visual analog scale, CSS central sensitivity syndrome.
Figure 2VAS pain scores at 1 month before, and 3 and 6 months after total hip arthroplasty in patients with and without CSSs. ‡P < 0.001. VAS visual analog scale, CSS central sensitivity syndrome, Pre 1 month before surgery, 3m 3 months after surgery, 6m 6 months after surgery.
Figure 3JHEQ scores at 6 months after total hip arthroplasty in patients with and without CSSs. (A) VAS satisfaction on JHEQ. (B) Pain, function, mental, and total scores on JHEQ. *P < 0.05 and ‡P < 0.001. VAS visual analog scale, CSS central sensitivity syndrome, JHEQ Japanese Orthopedic Association Hip-Disease Evaluation Questionnaire.
Impact of the number of central sensitivity syndrome diagnoses on post-operative Japanese Orthopaedic Association Hip-Disease Evaluation Questionnaire scores in patients with hip osteoarthritis: multiple regression analyses (N = 173).
| Outcome (JHEQ) | The number of CSSs diagnoses | β | 95% Confidence interval | P-values | R2 (adjusted R2) |
|---|---|---|---|---|---|
| Satisfaction | One | − 0.181 | − 0.331 to − 0.031 | 0.105 (0.067) | |
| Two or more | − 0.175 | − 0.327 to − 0.025 | |||
| Pain | One | − 0.093 | − 0.247 to 0.060 | 0.233 | 0.062 (0.022) |
| Two or more | − 0.175 | − 0.329 to − 0.020 | |||
| Function | One | − 0.067 | − 0.221 to 0.089 | 0.399 | 0.051 (0.010) |
| Two or more | − 0.067 | − 0.222 to 0.088 | 0.397 | ||
| Mental | One | − 0.110 | − 0.265 to 0.045 | 0.163 | 0.051 (0.010) |
| Two or more | − 0.073 | − 0.228 to 0.082 | 0.356 | ||
| Total | One | − 0.105 | − 0.259 to 0.048 | 0.177 | 0.067 (0.027) |
| Two or more | − 0.122 | − 0.278 to 0.035 | 0.142 |
All models were adjusted for sex, age, body mass index, duration of hip pain, and pre-operative visual analog scale for pain. Statistically significant P-values (< 0.05) are indicated in bold.
CSS central sensitivity syndrome, JHEQ Japanese Orthopaedic Association Hip-Disease Evaluation Questionnaire, β standardized partial regression coefficient.